✨ Free AI Report
Stallergenes Greer: Key Facts, Business Model & Financial Analysis Read the overview below or get the full interactive report with Cyborg Score, analyst debate audio & saved-company playlists — free, no credit card.
Get Free Report →
Home Company Research Stallergenes Greer
Company Research

Stallergenes Greer: Business Overview, Financials & Competitive Analysis

Stallergenes Greer scores 7/10 on the AskCyborg Cyborg Score (Strong). Market-leading privately-held allergen immunotherapy company with expanding manufacturing capacity, proven M&A capability, and global presence in a resilient specialty pharma segment. Stallergenes Greer demonstrates strong strategic positioning through consistent acquisitions (Entomon in January 2026, Palforzia in 2023), significant capital investment, and market leadership in allergen immunotherapy. The company operates across.

What is Stallergenes Greer's industry? Stallergenes Greer (stallergenesgreer.com) operates in Pharmaceuticals. AskCyborg classifies Stallergenes Greer under Pharmaceuticals in its company registry.

Stallergenes Greer is a leading global biopharmaceutical company specialising in allergen immunotherapy for human and veterinary use, with activities spanning the full value chain from product development and commerci...

7/ 10Strong

Cyborg Score thesis

Market-leading privately-held allergen immunotherapy company with expanding manufacturing capacity, proven M&A capability, and...

Read the full analyst-debate transcript →
Industry Pharmaceuticals
4 named competitors
4 recent developments
11 analyst dimensions
Synthesized from analyst-debate stress-testing across 11 dimensions and hundreds of data points. Methodology →
Cyborg Score recalibrated: September 14, 2026
AI-Verified Research
30+ Page Report

Get the Latest Stallergenes Greer Report

Up-to-date AI-powered research, analyst debate audio & saved-company playlists

Get Current Report Free
✓ No credit card required
or get it by email

Analyst-debate audio for Stallergenes Greer

AskCyborg analysts argue the bull and bear cases for Stallergenes Greer across 11 stress-tested dimensions. Listen on your commute -- faster than reading the 30-page report.

Play the free intro →
Free intro · Pro unlocks the full analyst debate
What's in This Report
Stallergenes Greer OverviewStrategic ProfileCompetitive LandscapeIndustry ContextKey facts
Get Interactive Report Freeor start reading below

Stallergenes Greer Overview

Pro stress-test →

Stallergenes Greer is a leading global biopharmaceutical company specialising in allergen immunotherapy for human and veterinary use, with activities spanning the full value chain from product development and commercialisation to allergy diagnosis and treatment. Backed by more than 120 years of expertise and innovation, the company's products reach patients in 46 countries worldwide.

Strategic Profile

Pro stress-test →

The company offers treatment of severe allergic rhinitis with allergen immunotherapy, including sublingual products, subcutaneous products, enzyme-linked immunosorbent assay components and prescription services. In June 2026, Stallergenes Greer announced a strategic investment of over €125 million by 2030 in its Antony site in France to expand and upgrade its industrial capacity.

Competitive Landscape

Pro stress-test →

Stallergenes Greer competes in the allergen immunotherapy space against major pharmaceutical companies with allergy divisions. Key competitors include companies offering sublingual immunotherapy (SLIT), subcutaneous immunotherapy (SCIT), and oral immunotherapy (OIT) products. The company's integrated approach covering diagnostics, therapeutic development, manufacturing, and distribution provides a comprehensive competitive advantage in the specialty allergy treatment market.

Industry Context

Stallergenes Greer operates in Pharmaceuticals.

Key facts

Founded: 2015 · Headquarters: Baar, Switzerland · Employees: 1,200 · Revenue: $100M–$1B (estimated)

What the analysts stress-tested

The top findings that survived the multi-agent debate for Stallergenes Greer.

  • Announced €125M+ strategic investment in French manufacturing facility through 2030 (June 2026)
  • Acquired Entomon s.r.l., Italy's only company extracting pure Hymenoptera venom for immunotherapy, with close expected by January 2026
+2 more stress-tested counter-arguments unlock with Pro. Read the full analyst debate →

Recent developments

Material events tracked by the AskCyborg corpus.

  • June 2026Announced €125M+ investment in Antony manufacturing facility through 2030
  • June 2026Presenting new clinical evidence on allergen immunotherapy at EAACI 2026 congress
  • +2 moreTrack every material event for Stallergenes Greer as it happens. Explore monitoring →
Get alerted when Stallergenes Greer has a new material development →

Named competitors

Pulled from the analyst-debate framework. Click any competitor to see their Cyborg Score.

XolairAnti-IgE monoclonal antibody for allergic conditions→PalforziaOral immunotherapy for peanut allergy→Grastek/OralairSublingual immunotherapy tablets for grass/birch pollen allergy→RagwitekSublingual immunotherapy tablet for ragweed allergy→

Compare Stallergenes Greer with another company

Pick any company in the AskCyborg corpus to see side-by-side Cyborg Scores and insights.

vs
Side-by-side opens in your AskCyborg account

Industry context

Stallergenes Greer operates in Pharmaceuticals. See how the rest of the sector scores on the Cyborg framework.

Browse Pharmaceuticals research →
NEW · MCP server

Ask your AI assistant about Stallergenes Greer

Install the free AskCyborg MCP server in Claude, Cursor, Cline, Continue, or Windsurf and ask any of these in-line:

“Compare Stallergenes Greer and its top competitor on Cyborg Score”
“What did Stallergenes Greer do this quarter?”
“Is Stallergenes Greer a defensible business in 5 years?”
Install the MCP server (10 sec) →
Free, anonymous, no API key required

How AskCyborg builds confidence

⚔

Analyst debate, not single-author opinion

Every report is stress-tested by a panel of AI analysts arguing across 11 dimensions. The output is the part of the case that survived pushback.

📊

Recalibrated weekly

The Cyborg Score is recomputed weekly against fresh data. Recent material developments are continuously tracked and surfaced.

🔗

Methodology open at /methodology

The framework, dimensions, and band breakdowns are documented. The same company gets the same score from any analyst running the framework.

🔒

Free tier is free

No credit card to read the research. Pro adds saved-company audio playlists, monitoring, audio briefings on demand, and PDF export for $39/mo annual.

Sources: public filings, regulatory data, news flow, and proprietary analyst signals. Read the methodology →

Frequently asked questions

What does Stallergenes Greer do?+
Stallergenes Greer is a leading global biopharmaceutical company specialising in allergen immunotherapy for human and veterinary use, with activities spanning the full value chain from product development and commerci...
What is Stallergenes Greer's Cyborg Score?+
Stallergenes Greer has a Cyborg Score of 7/10 (Strong). The score synthesizes business model, financials, leadership, competitive position, technology, marketing, and ESG dimensions across hundreds of data points.
Who are Stallergenes Greer's main competitors?+
Named competitors include Xolair, Palforzia, Grastek/Oralair, Ragwitek. The full competitive landscape is in the AskCyborg report.
How can I get the full Stallergenes Greer research report?+
Get the report plus analyst-debate audio at askcyborg.com -- no credit card required for preview access. Pro adds saved-company audio playlists and monitoring.
How current is the Stallergenes Greer research?+
The Cyborg Score is recalibrated weekly. Recent developments are tracked continuously and surfaced in every report.

Track Stallergenes Greer over time

Pro members get saved-company audio playlists, Cyborg Score recalibrations, and monitoring for material events across the AskCyborg corpus.

See Pro features
From $39/mo annual

More Pharmaceuticals research

Companies in the same sector and named competitors, ranked by Cyborg Score.

7Novartis AG7Recordati Industria Chimica e Farmaceutica SpA6CSPC Innovation Pharmaceutical Co., Ltd.